Chemical and genetic engineering strategies to improve the potency of pharmaceutical proteins and enzymes

dc.contributor.author	Platis, D	en
dc.contributor.author	Labrou, NE	en
dc.date.accessioned	2014-06-06T06:48:22Z
dc.date.available	2014-06-06T06:48:22Z
dc.date.issued	2008	en
dc.identifier.issn	09298673	en
dc.identifier.uri	http://dx.doi.org/10.2174/092986708785132924	en
dc.identifier.uri	http://62.217.125.90/xmlui/handle/123456789/4115
dc.subject	Chemoselective ligation	en
dc.subject	Directed evolution	en
dc.subject	Expressed protein ligation	en
dc.subject	Native ligation	en
dc.subject	PEG	en
dc.subject	PEGylation	en
dc.subject	Protein and enzyme engineering	en
dc.subject	Rational protein design	en
dc.subject	Semisynthetic proteins	en
dc.subject.other	aciclovir	en
dc.subject.other	activated protein C	en
dc.subject.other	alpha conotoxin MII	en
dc.subject.other	alpha interferon	en
dc.subject.other	alpha interferon receptor	en
dc.subject.other	amino acid	en
dc.subject.other	asparaginase	en
dc.subject.other	DNA vaccine	en
dc.subject.other	Fc receptor	en
dc.subject.other	ganciclovir	en
dc.subject.other	macrogol	en
dc.subject.other	monoclonal antibody 2F5	en
dc.subject.other	novel erythropoiesis stimulating protein	en
dc.subject.other	peginterferon alpha2a	en
dc.subject.other	peginterferon alpha2b	en
dc.subject.other	polyaspartic acid	en
dc.subject.other	polylysine	en
dc.subject.other	polyvinyl alcohol	en
dc.subject.other	recombinant blood clotting factor 7a	en
dc.subject.other	recombinant DNA	en
dc.subject.other	recombinant erythropoietin	en
dc.subject.other	recombinant granulocyte colony stimulating factor	en
dc.subject.other	recombinant human insulin	en
dc.subject.other	streptokinase	en
dc.subject.other	T lymphocyte antibody	en
dc.subject.other	thymidine	en
dc.subject.other	trastuzumab	en
dc.subject.other	unindexed drug	en
dc.subject.other	urate oxidase	en
dc.subject.other	zidovudine	en
dc.subject.other	ligand	en
dc.subject.other	polymer	en
dc.subject.other	protein	en
dc.subject.other	acute lymphoblastic leukemia	en
dc.subject.other	antigenicity	en
dc.subject.other	antineoplastic activity	en
dc.subject.other	antiviral activity	en
dc.subject.other	chemical engineering	en
dc.subject.other	chemical modification	en
dc.subject.other	DNA synthesis inhibition	en
dc.subject.other	drug bioavailability	en
dc.subject.other	drug delivery system	en
dc.subject.other	drug design	en
dc.subject.other	drug efficacy	en
dc.subject.other	drug half life	en
dc.subject.other	drug potency	en
dc.subject.other	drug receptor binding	en
dc.subject.other	drug research	en
dc.subject.other	drug structure	en
dc.subject.other	enzyme engineering	en
dc.subject.other	gene technology	en
dc.subject.other	genetic engineering	en
dc.subject.other	genetic variability	en
dc.subject.other	genomics	en
dc.subject.other	human	en
dc.subject.other	immunogenicity	en
dc.subject.other	nonhuman	en
dc.subject.other	protein engineering	en
dc.subject.other	protein glycosylation	en
dc.subject.other	protein purification	en
dc.subject.other	proteomics	en
dc.subject.other	review	en
dc.subject.other	site directed mutagenesis	en
dc.subject.other	structure analysis	en
dc.subject.other	virus infection	en
dc.subject.other	chemical structure	en
dc.subject.other	chemistry	en
dc.subject.other	directed molecular evolution	en
dc.subject.other	genetics	en
dc.subject.other	molecular library	en
dc.subject.other	protein conformation	en
dc.subject.other	synthesis	en
dc.subject.other	Amino Acids	en
dc.subject.other	Directed Molecular Evolution	en
dc.subject.other	Drug Design	en
dc.subject.other	Genetic Engineering	en
dc.subject.other	Humans	en
dc.subject.other	Ligands	en
dc.subject.other	Models, Molecular	en
dc.subject.other	Molecular Structure	en
dc.subject.other	Polymers	en
dc.subject.other	Protein Conformation	en
dc.subject.other	Proteins	en
dc.subject.other	Small Molecule Libraries	en
dc.title	Chemical and genetic engineering strategies to improve the potency of pharmaceutical proteins and enzymes	en
heal.type	other	en
heal.identifier.primary	10.2174/092986708785132924	en
heal.publicationDate	2008	en
heal.abstract	Over the last decade there has been significant progress in understanding the molecular basis of disease processes. At the same time the technological advances in the area of genomics and the efforts in proteomics research have increased the possibility of discovering many proteins with defined therapeutic functions. A large number of these proteins have found clinical application. Despite the importance of proteins as therapeutic agents, they have a number of disadvantages in comparison to small-molecule drugs, including immunogenicity and antigenicity, poor efficacy and oral bioavailability as well as, in many cases, short serum half-lives. To date, the most promising approaches for improving protein therapeutics rely on the use of genetic engineering and site-specific chemical synthesis/modification techniques. Improving the potency of protein drugs by employing modern recombinant DNA technologies and novel chemical synthesis techniques is of primary importance, not only because of the enormous medicinal benefit but also because of the significant economic edge an improved drug can provide in today's competitive market. ©2008 Bentham Science Publishers Ltd.	en
heal.journalName	Current Medicinal Chemistry	en
dc.identifier.issue	19	en
dc.identifier.volume	15	en
dc.identifier.doi	10.2174/092986708785132924	en
dc.identifier.spage	1940	en
dc.identifier.epage	1955	en